|
|
|
|
Rating: Overweight COV
96.15 %
COVIDIEN LTD. COMMON SHARES (COV) rated Overweight with price target $62 by Barclays
Posted on: Tuesday, May 8, 2012 1:25 PM ET by Barclays
Barclays rated Overweight COVIDIEN LTD. COMMON SHARES (NYSE: COV) on 05/08/2012, when the stock price was $54.40. Since
then, COVIDIEN LTD. COMMON SHARES has gained 96.16% as of 01/26/2016's recent price of $106.71. If you would have followed this Barclays's recommendation on COV, you would have gained 96.15% of your investment in 1358 days.
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines, including Surgical Devices, Energy-Based Devices, Respiratory and Monitoring Solutions, Patient Care and Safety Products, Imaging Solutions, Pharmaceutical Products, Medical Supplies and Retail Products.
Barclays
|
|
Date/Time (ET) | Symbol | Rating | Term | Price (*) | Target |
6/18/2014 12:00 AM |
COV
|
Buy
|
|
91.01
|
93.00
|
|
|
Date/Time (ET) | Symbol | Rating | Term | Price (*) | Target |
3/6/2014 12:25 PM |
COV
|
Buy
|
|
72.09
|
82.00
|
12/5/2013 2:25 PM |
COV
|
Buy
|
|
67.45
|
77.00
|
8/2/2013 1:25 PM |
COV
|
Buy
|
|
63.18
|
72.00
|
5/7/2013 2:25 PM |
COV
|
Buy
|
|
65.00
|
74.00
|
1/28/2013 1:25 PM |
COV
|
Buy
|
|
62.55
|
70.00
|
5/8/2012 1:25 PM |
COV
|
Buy
|
|
54.40
|
62.00
|
(*) Stock Price at the time of the recommendation.
|
|